C1orf106 Human shRNA Plasmid Kit (Locus ID 55765)
CAT#: TR306059
C1orf106 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
C1orf106 mouse monoclonal antibody, clone OTI6A6 (formerly 6A6)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | C1orf106 Human shRNA Plasmid Kit (Locus ID 55765) |
Locus ID | 55765 |
UniProt ID | Q3KP66 |
Synonyms | C1orf106 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | C1orf106 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 55765). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001142569, NM_018265, NM_018265.1, NM_018265.2, NM_018265.3, NM_001142569.1, NM_001142569.2, BC106877, NM_001367290, NM_001367289, NM_018265.4, NM_001142569.3 |
Summary | Expressed in peripheral macrophages and intestinal myeloid-derived cells, is required for optimal PRR (pattern recognition receptor)-induced signaling, cytokine secretion, and bacterial clearance. Upon stimulation of a broad range of PRRs (pattern recognition receptor) such as NOD2 or TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9, associates with YWHAQ/14-3-3T, which in turn leads to the recruitment and activation of MAP kinases and NF-kappa-B signaling complexes that amplifies PRR-induced downstream signals and cytokine secretion (PubMed:28436939). In the intestine, regulates adherens junction stability by regulating the degradation of CYTH1 and CYTH2, probably acting as substrate cofactor for SCF E3 ubiquitin-protein ligase complexes. Stabilizes adherens junctions by limiting CYTH1-dependent ARF6 activation (PubMed:29420262).[UniProtKB/Swiss-Prot Function] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression
,Guan, H;Guo, Y;Liu, L;Ye, R;Liang, W;Li, H;Xiao, H;Li, Y;,
Cell Biosci
,PubMed ID 29632659
[INAVA]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...